Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MQ710 |
Synonyms | |
Therapy Description |
MQ710 is a cancer vaccine comprising a modified vaccinia virus Ankara engineered with deletion of the viral E5R gene and to express FLT3L and OX40L, which potentially increases interferon signaling and cytokine release, reduces immunosuppression, and enhances antitumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MQ710 | MQ-710|MQ 710 | MQ710 is a cancer vaccine comprising a modified vaccinia virus Ankara engineered with deletion of the viral E5R gene and to express FLT3L and OX40L, which potentially increases interferon signaling and cytokine release, reduces immunosuppression, and enhances antitumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05859074 | Phase I | MQ710 + Pembrolizumab MQ710 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Active, not recruiting | USA | 0 |